Apple
AAPL
Taylor Morrison Home
TMHC
D.R. Horton
DHI
Petroleo Brasileiro SA Petrobras
PBR
Vale SA
VALE
US Stock MarketDetailed Quotes
SLXN Silexion Therapeutics
- 1.180
- +0.020+1.72%
Close Mar 27 16:00 ET
- 1.200
- +0.020+1.68%
Post 20:01 ET
10.26MMarket Cap-0.13P/E (TTM)
1.200High1.130Low182.02KVolume1.140Open1.160Pre Close212.10KTurnover3.48%Turnover RatioLossP/E (Static)8.69MShares122.01852wk High-2.49P/B6.17MFloat Cap0.57552wk Low--Dividend TTM5.23MShs Float122.013Historical High--Div YieldTTM6.07%Amplitude0.575Historical Low1.165Avg Price1Lot Size
Market Insights
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Silexion Therapeutics Stock Forum
Benzinga· 1 min ago
Silexion Therapeutics Corp. ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced it has completed an expanded development plan for its next-generation siRNA candidate, SIL204, which the company'...
Revolutionary KRAS Cancer Treatment: Silexion Expands Development Strategy for SIL204
Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference
Friday, 21st March at 8:30 am
Grand Cayman, Cayman Islands, March 21, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced it has completed an expanded dev...
Silexion's Pancreatic Cancer Breakthrough: 56% Response Rate Despite Financial Headwinds
PESG Report: Silexion Therapeutics' Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment
Monday, 17th March at 8:15 am
Silexion Therapeutics (NASDAQ: SLXN) has reported breakthrough preclinical data for its SIL204 therapeutic candidate, showing promising results in treating KRAS-driven cancers, particularly pancreatic cancer. The orthotopic model studies demonstrated:
~70% reduc...
considering the overall market this is
moving higher
No comment yet